May 25, 2018
FDA OK’s AkaRx’s liver drug
The U.S. Food and Drug Administration has approved AkaRx’s Doptelet (avatrombopag) tablets to treat low blood platelet count (thrombocytopenia) in adults with…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
May 24, 2018
Lilly to seek replacement for oncology president
Eli Lilly said Thursday its senior vice president and president of Lilly Oncology, and the member of the company’s executive…
May 24, 2018
Novartis’s Zessly approved in Europe
Novartis’s Sandoz has secured European Commission’s approval for biosimilar Zessly, the company said Thursday.
May 24, 2018
Real-world evidence shows weight loss in people receiving Saxenda
People treated with Saxenda for weight management lost an average of 8.1 kg after six months in a real-world clinical…
May 23, 2018
Lilly’s psoriasis treatment first FDA approved to include data in psoriasis involving the genital area
Eli Lilly said Tuesday that the U.S. Food and Drug Administration (FDA) has approved a label update for Taltz injection 80 mg/mL to…
May 22, 2018
Circassia Pharmaceuticals presents positive data from tested long-acting muscarinic antagonists
Circassia Pharmaceuticals showed positive clinical data from two studies of Tudorza and Duaklir, nearing the a deal with AstraZeneca in the United…
May 21, 2018
4D pharma to investigate MRx0518 in multiple cancer settings
The Medicines and Healthcare products Regulatory Agency (MHRA) has cleared 4D pharma’s Clinical Trial Application for MRx0518, a live biotherapeutic…
May 21, 2018
AstraZeneca gets Lokelma approval
The US Food and Drug Administration (FDA) has approved Lokelma (sodium zirconium cyclosilicate), formerly ZS-9, for the treatment of adults…
May 18, 2018
FDA approves Aimovig for migraine
The US Food and Drug Administration (FDA) has approved Novartis’s and Amgen’s Aimovig (erenumab) for the preventive treatment of migraine in…
May 16, 2018
Sanofi, Regeneron explore Dupixent’s role in targeting Type 2 inflammation as an underlying cause of atopic dermatitis
Sanofi’s pivotal Phase 3 test of Dupixent (dupilumab) to treat moderate-to-severe atopic dermatitis in adolescents met its primary and key secondary…